• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by ARS Pharmaceuticals, Inc.

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers SPRY
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.